KCT0003652已完成未知
A randomized, open-label, single dose, crossover clinical study to compare the pharmacokinetic characteristics and the safety between oral administration of IR formulation of bepotastine and SR formulation of bepotastine in healthy adult male subjects
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 45(Year)（—）
- 性别
- Male
入选标准
- •1) Healthy male older than 19 to 45 years at the time of screening
- •2) Body weight more than 50kg and Body Mass Index(BMI) 18~29 kg/m2
- •? BMI = (weight [kg])/(height [m])2
- •3. Subject judged to be eligible by physical examination and interview conducted according to the study protocol. Thus, Subject should not have congenital/chronic disease or pathological symptoms/findings
- •4. Subject judged to be eligible by clinical tests such as hematology test, blood chemistry test, serum electrolyte test, urine test, Urine Microscopy urine test, serology test performed according to the study protocol
- •5. Subject who fully understands the clinical trials after in-depth explanation, volunteers to join the clinical trials and signs inform consent
排除标准
- •1) Subject currently with or has a history of cardiovascular , respiratory, hepatic, renal, neurological, endocrine, hemato-oncology, psychiatric, urinary diseases that is clinically significant
- •2) Subject with a history of significant hypersensitivity or clinically significant hypersensitivity reaction to Bepotastine and other drugs (aspirin, antibiotic…etc.)
- •3) Systolic blood pressure ?100mmHg or ? 150mmHg, diastolic blood pressure?55mmHg or ? 95mmHg
- •4) Subject with the following results in the clinical laboratory tests
- •- Aspartate Transaminase(AST) or Alanine Transaminase(ALT) > 2 x upper limit of normal range
- •- Total Bilirubin > 2.0 mg/dl
- •- CK > 2 x upper limit of normal range
- •- eGFR < 60 mL/min/1.73m2
- •5) Subject who takes alcohol > 21 units/week, 1unit=10g=12.5ml of pure alcohol) or can’t stop drinking during the clinical trials
- •6) Subject who smokes> 10 cigarettes/day or can’t stop smoking during the clinical trials
- •7) Taking medication involved in other clinical trials within 90 days before the first administration
- •8) Whole blood donation within 60 days or component blood donation within 30 days before the first administration
- •9) Taking Prescription drug (ETC) or oriental medicine within two weeks and any OTC within 2 weeks before the first administration
- •10) Taking metabolizing enzyme inducers or inhibitors such as barbitals within 30 days before the first administration
- •11) Subject with mental illness or substance abuse
- •12) Consumption of food which can significantly change the absorption, distribution, metabolism and excretion of a drug within 7 days before the first administration (such as grapefruit or its components)
- •13) Those who do not agree with the approved method of contraception during the clinical trial
- •14) Patients judged as inadequate and clinical trials to test self-determined target for any reason
研究者
相似试验
已完成
不适用
Clinical study to compare the pharmacokinetic characteristics and the safety between Tenelitin tablet 20 mg and Tenelia tablet 20 mg in healthy adult subjectsKCT0003832Kyung Dong Pharmaceutical36
招募中
不适用
A randomized, open-label, single dose, crossover clinical study to investigate the effect of food on the pharmacokinetics of EL-1804 in healthy adult subjectsDiseases of the circulatory systemKCT0006897Elyson Pharmaceutical30
已完成
不适用
Clinical study to compare the effect of food on the pharmacokinetic characteristics and the safety after oral administration of SR formulation of bepotastine in healthy adult subjectsDiseases of the skin and subcutaneous tissueKCT0004393Chungbuk National University Hospital30
已完成
不适用
A clinical trial to investigate safety/tolerability and pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 tablets) compared to co-administration of Evogliptin 5 mg and Metformin XR 1000 mg after single oral administration in healthy male volunteersEndocrine, nutritional and metabolic diseaseKCT0001692Dong-A ST36
已完成
不适用
The aim of this study is to compare and evaluate the pharmacokinetic properties and safety of oral administration of KD4002Endocrine, nutritional and metabolic diseasesKCT0007759Kyung Dong Pharmaceutical32